All In Biotech

Drug Trial Radar · NCT01960348

APOLLO: The Study of an Investigational Drug, Patisiran (ALN-TTR02), for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis

APOLLO: A Phase 3 Multicenter, Multinational, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Patisiran (ALN-TTR02) in Transthyretin (TTR)-Mediated Polyneuropathy (Familial Amyloidotic Polyneuropathy-FAP)

Last checked: Nov 19, 2026Latest source record: Apr 22, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 225 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

225

Actual

Start

Nov 2013

Primary completion

Aug 2017

Study completion Aug 2017

Sponsor

Lead sponsor
Alnylam PharmaceuticalsAlnylam Pharmaceuticals (ALNY)
Sponsor type
Industry
First posted
Oct 10, 2013

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 85 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the safety and efficacy of patisiran (ALN-TTR02) in patients with transthyretin (TTR) mediated amyloidosis. An open-label, single-arm, long-term follow-up extension study NCT02510261 (ALN-TTR02-006) was initiated to provide participants who completed this study with continued patisiran-LNP (lipid nanoparticle) treatment.

Conditions

  • TTR-mediated Amyloidosis
  • Amyloidosis, Hereditary
  • Amyloid Neuropathies, Familial
  • Familial Amyloid Polyneuropathies
  • Amyloid Neuropathies
  • Amyloidosis, Hereditary, Transthyretin-Related

Interventions

  • patisiran (ALN-TTR02)Drug

    administered by intravenous (IV) infusion

  • Sterile Normal Saline (0.9% NaCl)Drug

    administered by intravenous (IV) infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Modified Neuropathy Impairment Score +7 (mNIS+7)Time frame: 18mo

Locations

52 sites in 21 countries. Site status is shown where the registry gives one.

  • Clinical Trial Site

    La Mesa, California

  • Clinical Trial Site

    Orange, California

  • Clinical Trial Site

    Denver, Colorado

  • Clinical Trial Site

    Chicago, Illinois

  • Clinical Trial Site

    Baltimore, Maryland

  • Clinical Trial Site

    Boston, Massachusetts

  • Clinical Trial Site

    Detroit, Michigan

  • Clinical Trial Site

    Rochester, Minnesota

  • Clinical Trial Site

    St Louis, Missouri

  • Clinical Trial Site

    New York, New York

  • Clinical Trial Site

    New York, New York

  • Clinical Trial Site

    Durham, North Carolina

  • Clinical Trial Site

    Portland, Oregon

  • Clinical Trial Site

    Buenos Aires, Argentina

  • Clinical Trial Site

    Westmead, Australia

  • Clinical Trial Site

    Ribeirão Preto, Brazil

  • Clinical Trial Site

    Rio de Janeiro, Brazil

  • Clinical Trial Site

    São Paulo, Brazil

  • Clinical Trial Site

    Sofia, Bulgaria

  • Clinical Trial Site

    Vancouver, British Columbia, Canada

  • Clinical Trial Site

    Nicosia, Cyprus

  • Clinical Trial Site

    Bourdeaux, France

  • Clinical Trial Site

    Créteil, France

  • Clinical Trial Site

    Le Kremlin-Bicêtre, France

  • Clinical Trial Site

    Lille, France

  • Clinical Trial Site

    Marseille, France

  • Clinical Trial Site

    Heidelberg, Germany

  • Clinical Trial Site

    Münster, Germany

  • Clinical Trial Site

    Regensburg, Germany

  • Clinical Trial Site

    Pavia, Italy

  • Clinical Trial Site

    Rome, Italy

  • Clinical Trial Site

    Sicily, Italy

  • Clinical Trial Site

    Aichi, Japan

  • Clinical Trial Site

    Kumamoto, Japan

  • Clinical Trial Site

    Matsumoto, Nagano, Japan

  • Clinical Trial Site

    Kuala Lumpur, Malaysia

  • Clinical Trial Site

    Mexico City, Mexico

  • Clinical Trial Site

    Groningen, Netherlands

  • Clinical Trial Site

    Lisbon, Portugal

  • Clinical Trial Site

    Porto, Portugal

Showing 40 of 52 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.